News

AlzheimAlert is Nymox’s unique, proprietary product that provides physicians with a valuable tool for the diagnosis of Alzheimer’s disease (AD) by measuring levels of a brain protein in

Zeljko Covic, chief executive officer of Pliva, said that the divestment of its Research Institute would allow the company to focus its efforts on the generics part of

During the initial phase of this collaboration, Apeiron Biologics and Evotec will jointly develop tailored biochemical and cellular assays, and Evotec will apply its skills in utilising such

The genotyping supports a study known as the Cancer Genetic Markers of Susceptibility (CGEMS), a National Cancer Institute (NCI) strategic initiative. The CGEMS initiative is designed to map

Aricept, which is co-promoted in the US by Eisai and Pfizer, is currently only approved for treatment of mild to moderate Alzheimer’s disease. Eisai Medical Research submitted the

While the decrease in AUA (American Urological Association) symptom score was consistent with that seen after other minimally invasive therapies there was no significant difference between treatment and

Preclinical data indicate that mesothelin is highly over-expressed in tumors of patients with pancreatic adenocarcinoma and other prevalent cancers including non-small lung carcinoma, ovarian carcinoma and mesotheliomas. Research

The agreement between the companies provides for the transfer of Geron’s vaccine production process to Cambrex and the current good manufacturing practices (cGMP) manufacture of GRNVAC1 by Cambrex.

The submission completes the “rolling” new drug application (NDA) that was initiated last August, under the continuous marketing application (CMA) pilot 1 program. AA amyloidosis is a progressive